SBIR/STTR Research Award

Method for Analyzing and Isolating Stem Cells

Award identifier 990d99b34c025fe0db8e7b6a174e6d681adc13a1cb9b971cda442e4a1841ee82Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$582,660

Program and phase

SBIR · Phase II

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ONE CELL SYSTEMS, INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): In recent years, it has become clear that the majority of cell surface markers are shared by many types of stem and progenitor cells. Thus the ability to separate unique cell sub-populations using current methods is limited. Although it is known that stem cells secrete specific factors into the extracellular space, it is difficult to characterize secretory activity of individual viable cells within a heterogeneous population. Association of the secreted factor(s) with a specific cell type provides an additional marker that can be used to characterize the cell and permit separation of cells while maintaining viability. Combining immunophenotyping with secretory profile is powerful approach for both research and eventual therapeutic applications. Development of new, reliable methods for analyzing and recovering single, viable stem cells based on secretory profile combined with expression of cell surface antigens is of considerable interest. The GMD Stem Cell Assay addresses the need for a functional, multiparameter, single cell assay that does not compromise cell viability, physiological state, and functionality. Phase I research optimized the assay for use with several experimental hematopoietic models. Phase II research will expand use of the assay with other models, including endothelial progenitor cells. This assay format can be widely used for immunological studies, including stem cell research and clinical applications. By providing a reliable method for analyzing and recovering single, viable stem cells based on secretory profile combined with expression of cell surface antigens, this assay format will be useful for stem cell research and clinical applications.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.